Results 121 to 130 of about 55,577 (266)

Security enhancement using scalable Blockchain-based Multi-Factor Authentication (BMFA). [PDF]

PLoS One
Rahman F, Fatima A, Hassan M, Al-Zyoud M, Alfaidi A, Maktoof MAJ, Ghazal TM.   +6 more
europepmc   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

Molecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Development of the authentication and authorization processes for the iAgree portal, a platform for patient-controlled data sharing across health systems. [PDF]

JAMIA Open
Soohoo SL, Keller MS, Chen Y, Hu D, Huang SC, Kuo TT, Leder C, Lu X, Meeker D, Morse B, Moyse H, Nagaraj G, Nguyen AT, Schilling LM, Soares A, Whooley MA, Zheng K, Ohno-Machado L.   +17 more
europepmc   +1 more source

Single‐cell DNA methylation profiling: Technologies, computation, and applications in precision oncology

Molecular Oncology, EarlyView.
Single‐cell DNA methylation (scDNAme) profiling maps epimutational clonal evolution, revealing mechanisms of malignancy and therapeutic resistance across diverse cancer types. By providing a high‐resolution landscape of intratumoral heterogeneity, these technologies empower precise patient stratification, guide the development of enhanced ...
Ik Soo Kim
wiley   +1 more source

A PUF-Based Secure and Lightweight Authentication Protocol for Medical IoT Environments. [PDF]

Sensors (Basel)
Lim H, Park Y, Park Y.
europepmc   +1 more source

Interferon beta drives therapy resistance in a patient‐derived model of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Interferon type 1 (IFN‐1) production and signaling is associated with the acquisition of therapy resistance, following chronic DNA damage, via Interferon‐related DNA damage resistance signature (IRDS) gene expression. An alternative, DNA damage‐independent role of sustained IFN‐1 mediated resistance was identified and characterized by the emergence of ...
Ashlyn Conant, Tise Suzuki, Kiera McGivney, V. S. S. Abhinav Ayyadevara, Sharon Asariah, Jay Deng, Ethan Nyein, Jacqueline Coats, Gary Yu, Yevgeniya J. Ioffe, Christian Hurtz, Juli J. Unternaehrer   +11 more
wiley   +1 more source

PufCB-Auth: A lightweight continuous multi-factor authentication scheme integrated PUF with charging behavior features for EV charging. [PDF]

PLoS One
Zhang C, Zhang K, Zhang C, Chen S, Ma J, Fu S, Yang C, Wang Y, Zhang N, Zhao L, Ying X, He L, Ma H.   +12 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

Molecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin, Irina Kube‐Golovin, Anatolii Romaniuk, Gunther Wennemuth   +3 more
wiley   +1 more source

Study on the Effectiveness of NH4H2PO4 Powder in Inhibiting the Pyrolysis Gas Flame of Coniferous Woods and Its Suppression Mechanism

ACS Omega
Jian Gao, Kai Zhang, Guangxin Li, Kaikai Liu, Yiqing Chen, Jian Lu, Jianhao Wang, Haoyang Li, Bing Zhang   +8 more
doaj   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

Molecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas, Barbara Karakyriakou, Patricia C. Muskus, Alyssa M. Roberts, Justin Rendleman, Alexa Warren, Hanxu Lu, Kimberly A. Birmingham, Malone K. Friedman, Abigail E. Goen, Huijuan Yang, Owen M. Wilkins, Fred W. Kolling, Eugene Demidenko, Julie M. Jorns, Brock C. Christensen, Todd W. Miller   +16 more
wiley   +1 more source